Utebzi - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Biotech laboratory image illustrating Spero Therapeutics’ shift from Utebzi antibiotic approval to a royalty-funded SP001 immunology strategy. Representative image.

Read More

Pharma Industry News

Spero Therapeutics (Nasdaq: SPRO) pivots to immunology after Utebzi approval and $105m financing

Spero Therapeutics uses Utebzi royalties to fund an Innovent immunology pivot. Read how SPRO’s cash runway, CD40L bet and stock discount fit together.

August 13, 2026

web analytics